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Abstract
Background: Major depression is a common mental health problem in the general population,
associated with a substantial impact on quality of life and societal costs. However, many depressed
patients in primary care do not receive the care they need. Reason for this is that pharmacotherapy
is only effective in severely depressed patients and psychological treatments in primary care are
scarce and costly. A more feasible treatment in primary care might be computerised cognitive
behavioural therapy. This can be a self-help computer program based on the principles of cognitive
behavioural therapy. Although previous studies suggest that computerised cognitive behavioural
therapy is effective, more research is necessary. Therefore, the objective of the current study is to
evaluate the (cost-) effectiveness of online computerised cognitive behavioural therapy for
depression in primary care.
Methods/Design: In a randomised trial we will compare (a) computerised cognitive behavioural
therapy with (b) treatment as usual by a GP, and (c) computerised cognitive behavioural therapy in
combination with usual GP care. Three hundred mild to moderately depressed patients (aged
18–65) will be recruited in the general population by means of a large-scale Internet-based
screening (N = 200,000). Patients will be randomly allocated to one of the three treatment groups.
Primary outcome measure of the clinical evaluation is the severity of depression. Other outcomes
include psychological distress, social functioning, and dysfunctional beliefs. The economic evaluation
will be performed from a societal perspective, in which all costs will be related to clinical
effectiveness and health-related quality of life. All outcome assessments will take place on the
Internet at baseline, two, three, six, nine, and twelve months. Costs are measured on a monthly
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basis. A time horizon of one year will be used without long-term extrapolation of either costs or
quality of life.
Discussion: Although computerised cognitive behavioural therapy is a promising treatment for
depression in primary care, more research is needed. The effectiveness of online computerised
cognitive behavioural therapy without support remains to be evaluated as well as the effects of
computerised cognitive behavioural therapy in combination with usual GP care. Economic
evaluation is also needed. Methodological strengths and weaknesses are discussed.
Trial registration: The study has been registered at the Netherlands Trial Register, part of the
Dutch Cochrane Centre (ISRCTN47481236).
Background
Major depression is a common mental health problem in
the general population [1] and it is reported to be the sec-
ond most common and costly mental health problem in
general practice [2]. Depression is associated with sub-
stantial decreases in quality of life through its impact on
physical, social and emotional functioning, and well-
being [3,4]. By 2020, depression is estimated to be the sec-
ond leading contributor to the global burden of disease
[5]. Cost-of-illness studies reveal that the economic bur-
den of depression is considerable [6-8].
Difficulties in the treatment of depression in primary care
The general practitioner (GP) is the major health care pro-
vider involved in the primary care treatment of depres-
sion. In the Dutch health care system the GP is seen as a
gatekeeper, and as a result patients view their GP as a key
figure in the detection and treatment of depression [9].
Despite this, many depressed patients remain undetected
[10-12]. Even when the depressive complaints are being
recognised, many patients in primary care do not receive
the care they need. There are several reasons for this. First,
time for the management of psychosocial problems is
lacking [13]. Second, pharmacotherapy is only effective in
extremely depressed patients [14], and many patients
refuse medication or comply poorly [15]. Third, effective
non-pharmacological treatment options, such as psycho-
therapy, in primary care are scarce or not feasible [16].
Consequently, only a limited group of depressed patients
in primary care receives effective treatment.
Computerised cognitive behavioural therapy in primary 
care
Cognitive behavioural therapy (CBT) is one the most
widely researched forms of psychotherapy. Cognitive
behavioural therapy (CBT) has proven to be as effective as
pharmacotherapy in the acute phase of mild to severe
depression, and seems even more effective in the preven-
tion of recurrence and relapse [17-19]. Despite its effec-
tiveness, face-to-face CBT in primary care has some major
limitations. There are not enough well trained therapists,
it is costly, there are waiting lists, and patients may feel
reluctant to enter psychotherapy. An alternative treatment
in primary care might be computerised cognitive behav-
ioural therapy (CCBT): a computer program based on the
principles of CBT. The level of therapist support can vary
considerably in CCBT. It can be offered as a self-help inter-
vention without or with only minimal support. Previ-
ously, written self-help based on CBT seemed a promising
treatment for depression [20]. In a primary care setting,
positive outcomes were found regarding the (cost-) effec-
tiveness of written self-help with minimal contact in sub-
threshold depression relative to care as usual provided by
the GP [21,22].
CCBT for primary care seems promising; it provides an
acceptable alternative to pharmacotherapy, it can save cli-
nicians' time, and the costs are low compared with face-
to-face CBT. Furthermore, CCBT has a high accessibility,
the number of referrals to secondary care by a GP can be
reduced, and waiting lists for traditional CBT can become
shorter [23,24]. Next to that, CCBT may fit very well in a
stepped care program, and may function as a first step in
the treatment of depression [25]. In a recent systematic
review [23], it was concluded that CCBT is a feasible, effec-
tive and acceptable treatment for depression. However,
most research on the efficacy of CCBT has been conducted
in the general population or within clinical or specialist
settings. To our knowledge, only one study, so far, inves-
tigated the efficacy of CCBT for depression in primary care
[26], and it was shown that CCBT (delivered on a personal
computer in the general practice) is more effective than
usual care by a GP in mild to moderate depression and
anxiety. Furthermore, this intervention seemed promising
regarding the cost-effectiveness compared with usual GP
care. CCBT was both more effective and more costly com-
pared with usual GP care. When willing to pay for an addi-
tional unit of effect, CCBT could be very cost-effective. If a
value of £40 is placed on a unit reduction on the Beck
Depression Inventory, the probability of CCBT being cost-
effective is in excess of 80%. At a value of £5000 for 1
quality-adjusted life-year (QALY), the study showed that
there is an 85% chance of CCBT being more cost-effective,
and at a value of £15000 per QALY it exceeds a 99%BMC Public Health 2008, 8:224 http://www.biomedcentral.com/1471-2458/8/224
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chance of being cost-effective [27]. Nevertheless, more
research is necessary; so far only this one study has con-
ducted an economic evaluation of CCBT, and the effects
of CCBT in combination with usual care by a GP are still
unknown. In addition the efficacy of CCBT via the Inter-
net in primary care remains to be evaluated. The Internet
can offer further advantages in comparison to CCBT on a
stand-alone computer; it is easily accessible and it can be
used at home, anonymously, and it is available 24/7.
Current study
In the present study we aim to evaluate the (cost-) effec-
tiveness of online CCBT for mild to moderate depression
in primary care. In a randomised trial we will compare (a)
CCBT with (b) treatment as usual (TAU) by a GP, and (c)
CCBT in combination with TAU. In a recent Dutch study
of Spek et al. (2007), the same CCBT program has shown
to be equally effective as group CBT in people over 50
years old with subthreshold depression [28]. Based on the
results from a recent systematic review [23] we hypothe-
sise that CCBT will be more effective than TAU by a GP.
Furthermore, we hypothesise that CCBT in combination
with TAU will be more effective than CCBT alone by
increasing treatment adherence. Although some studies
have shown that for mild depression a combination of
pharmacotherapy and psychotherapy does not appear
more effective than psychotherapy alone [29], other stud-
ies suggested that patients receiving combined treatments
were more likely to stay in treatment and comply to the
treatment protocol [30].
Regarding the economic evaluation we hypothesise the
following. The self-help intervention CCBT alone implies
costs of time spent by the patient on the treatment and
costs of the development of the program, while the TAU
treatment requires costs related to a GP consult and/or
medication. We hypothesise that from a societal perspec-
tive, these costs of the intervention CCBT are comparable
to the costs of the intervention TAU. However, as a conse-
quence of our hypothesis that CCBT is more effective than
TAU, we expect that CCBT will be more preventive in
health care use and productivity loss during the follow-up
period, and thus result in lower costs compared with TAU
by a GP. As a consequence of the expected increase of
effectiveness (in terms of depression and quality of life)
and decrease of costs, we hypothesise that CCBT is more
cost-effective than TAU by a GP. Hypotheses about the
intervention CCBT in combination with TAU are that it is
both more costly and more effective compared with stand
alone CCBT or TAU.
Methods
Design
We will conduct a randomised controlled trial. Patients
will be randomly allocated to one of the three following
conditions: (a) CCBT, (b) TAU by a GP, and (c) a combi-
nation of CCBT and TAU by a GP. The design of the study
and the anticipated flow of the participants are graphically
shown in Figure 1. The Medical and Ethical Committee of
Maastricht University approved the study protocol. The
study is registered at the Netherlands Trial Register, part of
the Dutch Cochrane Centre (ISRCTN47481236).
Study population
The patient population we aim to investigate consists of
300 mild to moderately depressed adults. Patients are eli-
gible to participate if they meet the following criteria: age
18 to 65 years; access to the Internet at home; at least mild
to moderate depressive complaints (BDI-II score > 16),
although a DSM-III-R diagnosis of major depression was
not required; duration of depressive complaints 3 months
or more; no current psychological treatment for depres-
sion; no continuous antidepressant treatment for 3
months or more prior to entry; fluent in Dutch language;
no alcohol and/or drug dependence; and no severe psy-
chiatric co-morbidity (e.g. psychotic disorders).
Sample size
Power calculations are based on elementary head-to-head
comparisons of CCBT versus usual care and CCBT versus
the combined treatment (t-test). A clinically relevant treat-
ment effect is derived from the only study of CCBT in pri-
mary care [26]. For a mean difference in change scores of
5 (SD 5.25) on the BDI-II, a sample size of 84 participants
per group is needed (power 90%, alpha 0.05). Adjusting
for potential study withdrawal (20%), we estimate that
100 participants per group are needed.
Recruitment
Participants will be recruited in the general population by
means of a large-scale Internet-based screening in the
South of the Netherlands. A random selection of individ-
uals (N = 200,000) will be sent an invitation letter to com-
plete a screening questionnaire (i.e. BDI for primary care)
via the Internet. The letters will be sent in weekly badges.
Six municipalities cooperate by issuing names and
addresses of their residents on a weekly base. The letters
will contain information on the study protocol as well as
log in codes for the questionnaires on the Internet. Partic-
ipants who score above the cut-off score of four on the
BDI for primary care [31] will be invited to visit the
research centre for an interview where final eligibility will
be assessed based on the in- and exclusion criteria. After
inclusion we will notify the patients' GP about his or her
participation in the study.
Randomisation and procedure
Randomisation will take place after informed consent is
obtained. An independent statistician will develop the
randomization code. Block randomization will be used toBMC Public Health 2008, 8:224 http://www.biomedcentral.com/1471-2458/8/224
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ascertain that each intervention consists of equally large
groups. The randomization code will be given to an inde-
pendent IT-specialist who will develop a computer pro-
gram to carry out the group allocation. On entry into the
trial the computer program provides the next available
number. The randomization code will not be revealed
until participant inclusion is complete. In view of the
nature of the treatments, blinding of the participants and
researchers is not possible.
Baseline assessment will take place at the research centre
before randomization. The questionnaires will be admin-
istered on a computer. All follow-up assessments will take
place at home via the Internet at two, three, six, nine and
twelve months after inclusion. Preceding an upcoming
assessment point, participants will receive an email alert.
If a participant fails to complete the assessment within
one week, an email-reminder will be sent. When the par-
ticipant still fails to fill out the questionnaires, a phone
call will be made.
Individuals will not be paid for participation, but will
receive a small fee for Internet use.
Flow of the participants Figure 1
Flow of the participants.BMC Public Health 2008, 8:224 http://www.biomedcentral.com/1471-2458/8/224
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Interventions
The CCBT program (named "colour-your-life") is an
online, multimedia, interactive, self-help computer pro-
gram for depression, and was developed by Riper and
Kramer (2004) [32] of the Trimbos-institute (the Nether-
lands Institute of Mental Health and Addiction). The pro-
gram is based on the principles of CBT and on the Dutch
version of the 'coping with depression course' of Lewin-
sohn [33,34]. The program consists of eight weekly 30-
minute sessions and a ninth booster session, although the
duration of sessions can vary among users. At the end of
each session homework-assignments are given, such as
keeping a 'mood diary'. Patients allocated to the interven-
tion CCBT or the combination CCBT and TAU will be
given log in codes by the researchers at inclusion and they
will access the program at home. No professional assist-
ance will be offered. The program was originally devel-
oped for people over 50-years old [28] and is adapted for
an adult population (18 to 65 years) for the current study.
GP's of patients allocated to CCBT only will be informed
about the participation and treatment allocation of their
patient.
In the TAU and CCBT&TAU group, participants will be
advised to contact their own GP. GPs of patients in the
TAU and the CCBT&TAU group will be sent a letter,
informing them about their patients' study participation,
and advising them to follow the depression guideline as
described by the Dutch College of General Practitioners
[35]. This guideline states that treatment should formally
consist of four to five biweekly consultations over the
course of nine weeks in combination with antidepressant
treatment if indicated. In case of suicidal risk, social dys-
function, symptom deterioration or non-improvement in
six to twelve weeks time, referral to specialist mental
health care settings is recommended. In practice however,
usual care is whatever the GP prescribes.
An integrity check will be performed to assess treatment
quality and protocol compliance using computer records
of the CCBT program and questionnaires assessing use of
GP and other health care (i.e. health care use question-
naire).
Instruments
Instruments will be used for the screening process, the
clinical outcome assessment and the economic evalua-
tion. In Table 1 an overview of all assessments per time
point is shown.
Beck Depression Inventory for Primary Care
The Beck Depression Inventory for Primary Care (BDI-PC)
is a screening instrument for depression consisting of
seven items derived from the Beck Depression Inventory
II. Each item is assessed at a 4-point Likert-scale (range 0
– 4). Several studies have proven its sound psychometric
properties [31,36,37]. A cut-off score of 4 was used in the
current study, since this has excellent sensitivity and spe-
cificity for identifying a diagnosis of major depression
[31].
Composite International Diagnostic Interview
To determine in- and exclusion criteria the computerised
Composite International Diagnostic Interview (CIDI-
auto) will be used. The CIDI is an extensive, fully struc-
tured diagnostic interview to assess lifetime and 12-
month DSM-III-R diagnoses. The CIDI can be used by lay-
interviewers and has acceptable reliability and validity
[38,39].
Beck Depression Inventory Second Edition
The Beck Depression Inventory II (BDI-II) will be used to
measure depressive severity. The total score is the sum of
the 21 items with a range of 0 (no depression) to 63
(severe depression). There has been consistent support for
the construct validity and reliability of the BDI-II in vari-
ous samples [40-42].
Table 1: Overview of instruments per time point
Instrument Screening Baseline 2 months 3 months 6 months 9 months 12 months
Demographic variables X
Beck Depression Inventory PC X
Composite International Diagnostic Interview X
B e c k  D e p r e s s i o n  I n v e n t o r y  I I X XXXXX
Symptom Checklist 90 X X X
Work and Social Adjustment Scale X X X
D y s f u n c t i o n a l  A t t i t u d e s  S c a l e X XXXXX
WHOQoL-BREF X X X
E u r o Q o l X XXXX
Productivity and disease questionnaire X XXXX
Note. In addition to the regular follow-up measurements, each month the health care use questionnaire will be administered.BMC Public Health 2008, 8:224 http://www.biomedcentral.com/1471-2458/8/224
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Functional impairment
Functional impairment will be assessed with the SF-36
Health Survey (SF-36), which consists of 36 items measur-
ing 8 multi-item scales. For each subscale items are coded,
summed, and transformed on to a scale from 0 (worst
possible health state measured by the questionnaire) to
100 (best possible health state). The SF-36 has good psy-
chometric properties in terms of validity, reliability, and
scale structure [43-45]. Additionally, the economic evalu-
ation will use the SF-6D utility, which is a quality of life
measure derived from the SF-36 [46].
Psychological distress
The Symptom Checklist (SCL-90) is a self-report symp-
tom inventory of psychopathology. The SCL-90 consists
of 90 items, each rated on a five-point scale of distress
from 'not at all' to 'extremely' [47,48]. The total score of
the SCL-90 can be used as an index of severity for general
psychological distress (score range 90–450) [49]. The
SCL-90 has a high degree of reliability and support has
been found for the validity [47].
Social functioning
The Work and Social Adjustment Scale (WSAS) is a self-
report scale of functional impairment attributable to an
identified problem. The WSAS consists of five items meas-
ured on an 8-point Likert-scale (0 to 8). A high score indi-
cates severe impairment. It has good psychometric
properties [50].
Dysfunctional attitudes
The Dysfunctional Attitude Scale form A (DAS-A) is a self-
report scale designed to measure the presence and inten-
sity of dysfunctional attitudes. The DAS-A consists of 40
items and each item consists of a statement and a 7-point
Likert-scale (7 = fully agree; 1 = fully disagree). The higher
the score, the more dysfunctional attitudes an individual
reports [51].
Quality of life measures for the economic evaluation
Measuring health-related quality of life is relevant in
patients with depression, since depression has a large
impact on the physical, social and emotional aspects that
are relevant and important to a patient's well-being [3,4].
An intervention aimed at treating depression is therefore
expected to have an impact on the perceived quality of
life. In addition, measuring generic quality of life facili-
tates the comparison of the effects on quality of life of our
intervention program with that of other interventions
[52]. Quality of life will be measured in three different
ways in this study by using the WHOQOL-BREF, the Euro-
Qol and the SF-6D.
The WHOQOL includes a broader range of mental health
aspects in its psychological domain compared to other
quality of life instruments and is therefore more feasible
to use in this study [53]. The WHOQOL-BREF is an abbre-
viated version of the WHOQOL-100, which has proven to
be a valid and reliable alternative [54,55]. The WHOQOL-
BREF measures four domains related to quality of life
(physical health, psychological health, social relation-
ships and environment) and includes two questions on
overall quality of life and general health [55].
Generic quality of life will be derived by means of the EQ-
5D of the EuroQol group. The EQ-5D consists of five
health state dimensions (mobility, self-care, usual activity,
pain/discomfort and anxiety/depression) on which the
respondent has to indicate his own health state [56,57].
The EuroQol will be assessed since it is a validated and
widely used quality of life instrument, both nationally
and internationally [58]. An advantage of the EuroQol is
that it is short and that an overall utility score for popula-
tion-based quality of life can be obtained, which facili-
tates comparisons with other interventions and health
states in other disease areas. A utility refers to the prefer-
ence that individuals or society may have for any particu-
lar set of health outcomes. It is indicated by a number
between 0 (the worst imaginable condition: death) and 1
(perfect health) [52]. Standardised value sets are available
to calculate the utility based on the EQ-5D. This study will
use the Dutch tariff and the original UK tariff to value
generic quality of life [58-60]. The utility scores of the EQ-
5D will be used to calculate the quality adjusted life year
(QALY) during the follow-up period by adjusting the
length of time affected through the health outcome by the
utility value [52].
An adapted version of the EuroQol is the EQ-5D+C, in
which a sixth domain (cognitive functions referring to
memory, concentration, coherence and IQ-level) is added
to the five existing domains of the EQ-5D [61-63]. This
sixth domain of the EQ-5D+C is also included in the ques-
tionnaire to provide additional information on quality of
life. However, since there is no tariff developed to com-
pute utility scores for the EQ-5D+C, utility scores and
QALYs will only be calculated based on the five domains
of the EQ-5D.
The SF-6D is a utility instrument based on the health-
related quality of life questionnaire SF-36. The utility
score is derived from 11 items of the SF-36 and is com-
posed of six dimensions of health (physical functioning,
role limitations, social functioning, pain, mental health,
and vitality). The SF-6D utilities will be derived by means
of the preference-based UK tariff [46].
Costs
Costs will be defined from the societal perspective. Within
our study we distinguish three cost-categories: health careBMC Public Health 2008, 8:224 http://www.biomedcentral.com/1471-2458/8/224
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sector costs, costs for the patient and family, and produc-
tivity costs [52].
A health care use questionnaire will be developed to
measure the psychological, paramedical, medical, paid
and informal care, participation in a self-help group, and
alternative treatments received by the patient on a
monthly base. This health care use questionnaire will be
based on an existing cost diary [64] and retrospective cost
questionnaires [65,66], and is adapted to depressive
patients. This questionnaire will provide information to
calculate health care sector costs by measuring the volume
of care provided, and out-of-pocket expenses, which are
part of the costs for the patient and family. The other part
of the patient and family costs will concern costs of travel-
ling and lost time due to the primary care intervention
TAU and/or CCBT. The time spent by a patient on CCBT
will be tracked by means of the computer-registered login
and logout data of the program. In the health care use
questionnaire the duration of a GP consult will be regis-
tered by the patient. The number of GP consults informs
on the number of travels from/to the GP, and will be
linked to average distances from/to a GP. Dutch guideline
prices will be used to value the costs of the health care
items [67]. If for specific cost-categories cost guidelines are
unavailable, average tariffs or shadow prices will be used.
The standard cost prices and tariffs of health care practi-
tioners include the integral costs, being all costs directly
and indirectly attributable to the cost unit.
For the measurement of production losses, the patient
modules B, C, D and E of the PROductivity and DISease
Questionnaire (PRODISQ) will be used [68,69]. These
modules consist of questions concerning the profession,
working situation, income, absence from work, compen-
sation mechanisms in case of absence for paid work and
productivity costs at work (efficiency loss) of the patient.
Productivity costs will be calculated according to the fric-
tion cost approach [67,70], using one general cost price
per lost hour of productivity [67]
Analyses
Clinical analyses
Data-analysis will include intention-to-treat analysis and
per-protocol analysis. Analysis will include elementary
head-to-head comparisons of the intervention groups as
well as more complicated multi-level analysis incorporat-
ing patients and time measurements if necessary. An
integrity check and a process evaluation will be performed
using qualitative methods of analysis. In case of missing
data, we will impute intermittent missing data using the
mean of the values of a previous and a subsequent time
point. Other missing data (i.e. missing values due to lost
to follow-up) will only be imputed when more then 15%
of the data are missing.
To test the main hypotheses, difference scores for all out-
come variables will be calculated (t0 minus tk) and com-
pared between the three groups using ANOVA. In case of
violation of assumptions, robust ANOVA can used [71].
We will then compute improvement effect sizes and
between-group effect sizes [72] or robust equivalents [see
[73]]. Next, we will calculate the number of patients who
showed reliable and clinically significant change on the
BDI-II using the method of Jacobson and Truax [74]. This
calculation is based on two components: (1) the extent to
which the pre-to-post-difference score is reliable taking
into account the measurement variability of the instru-
ment (reliable change; RC), and (2) the extent to which
post-treatments scores are clinically meaningful (clini-
cally significant change; CSC) [75]. Chi-square tests will
be used to test the frequency differences in RC, CSC and
RC+CSC between the three groups.
Economic evaluation
Since the follow-up period lasts one year and no extrapo-
lation over time will be executed, discounting of costs is
not necessary. All costs will be indexed to the year 2007 by
means of the price indexes of the Dutch Central Bureau of
Statistics (CBS).
For each patient, volumes of care, travels, lost time for
receiving care and lost productivity hours will be multi-
plied by the prices determined for each cost item. Based
on the costs per item, costs during the follow-up period
will be calculated as the cumulative costs per patient. The
costs at baseline and during the follow-up period of the
three groups will be compared by the non-parametric
bootstrapping method with confidence intervals in per-
centiles. By bootstrapping, samples of the same size as the
original data are drawn with replacement from the
observed data [76]. The quality of life and clinical out-
come variables will be compared between the three
groups at baseline and during the follow-up period using
ANOVA.
In case of baseline differences of costs, effectiveness, or
utility scores between the patient groups, corrections will
be performed [77-79]. The economic evaluation will con-
sist of a base-case cost-effectiveness and cost-utility analy-
sis, and sensitivity analyses. Uncertainty of parameter
estimates of the base-cases will be dealt with by these sen-
sitivity analyses [52]. In the base-cases, data will be ana-
lysed according to the intention-to-treat principle.
Incremental cost-effectiveness ratios (ICERs) will be deter-
mined on the basis of incremental costs and incremental
effects [52] of (a) stand alone CCBT compared with (b)
usual GP care, or (c) a combination of CCBT and usual GP
care. The primary outcome measure for the cost-effective-
ness analysis is depression measured by the BDI-II, and
for the cost-utility analysis the QALY based on the EQ-5D.BMC Public Health 2008, 8:224 http://www.biomedcentral.com/1471-2458/8/224
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The cost-effectiveness ratio will be stated in terms of costs
per point improvement on the BDI-II, the cost-utility ratio
will focus on the net cost per QALY gained. In our primary
analysis QALYs will be derived from the EQ-5D using the
UK-tariff. Scores on the quality of life domains derived
from the WHOQOL-BREF and the sixth domain of the
EQ-5D+C will be used to provide in-depth insight into the
quality-of-life.
Non-parametric bootstrap re-sampling techniques will be
used to explore uncertainty around estimates of cost-effec-
tiveness derived from the study sample [76]. Decision
uncertainty will be represented graphically by means of a
cost-effectiveness acceptability curve (CEAC) [52,80,81].
In addition, the net monetary benefit (NMB) will be used
to present the cost-effectiveness and cost-utility results in
monetary units. The NMB expresses the difference in
effects between the intervention groups in monetary val-
ues using the threshold willingness-to-pay for a unit of
effect, minus the difference in costs between the interven-
tions [52,82]. Since the value that society would place on
a unit reduction in BDI-II depression score is unknown,
different values will be assumed to calculate the NMB
[27]. Regarding the QALY, the Dutch Council of Public
Health and Care suggested in 2006 a ceiling of £80.000
per QALY per year [83]. Alternative values, ranging to
£80.000 per QALY, will be used to estimate the NMB.
The alternative threshold values of the NMB will be ana-
lysed in sensitivity analyses. Other aspects that can be part
of a sensitivity analysis are: varying the utility outcome
measure by using the SF-6D or alternative tariffs to value
the EQ-5D utility (Dutch tariff instead of the UK tariff), or
including other effectiveness measures used in the clinical
evaluation. Cost prices will be varied as minimum and
maximum cost price estimates. Next to the intention-to-
treat analysis, a per-protocol analysis can be performed.
Collaboration
The current study will be conducted in collaboration with
several disciplines. The Trimbos-institute (the Nether-
lands Institute of Mental Health and Addiction) will be
involved in the development and dissemination of CCBT.
The Pandora foundation (patient organization) acts as an
advisor on the design of the study and the dissemination
of the results. Several members of the project group work
as clinicians in secondary mental health care institutions
and have substantial professional contacts in the field.
The
Dutch College of General Practitioners (NHG) has been
informed about our plans and supports our initiative.
Additional research projects will be conducted in collabo-
ration with the Department of Health, Ethics and Society/
Metamedica and the Department of Health Organization,
Policy and Economics of the Maastricht University. For
instance, these projects will focus on topics like the
patient perspective on CCBT and quality of life aspects of
depression.
Discussion
Although in the last two decades research attention for
CCBT has grown, research on the effectiveness of CCBT
for depression in primary care is still in its infancy, espe-
cially CCBT offered via the Internet. More research evalu-
ating such interventions is necessary. Therefore, in the
current study we will evaluate the (cost-) effectiveness of
an online CCBT self-help program for mild to moderate
depression in primary care. We will compare CCBT with
treatment as usual by a GP, and with a combination of
both treatments.
Why do we need more research on CCBT in primary care?
There are several reasons why we are conducting this
study. First, the only study so far on CCBT in primary care
used a program that was delivered on a computer in the
general practice [26]. Since the Internet can increase the
accessibility of such an intervention, we will offer the
CCBT program on the Internet. In the Netherlands,
almost all of the general adult population has access to
Internet, and this will only increase in the next decade
[84]. Second, in the only other study on CCBT in primary
care [26], a nurse provided practical support at the start
and end of each session. We will study the effectiveness of
CCBT as a pure self-help intervention; no support or guid-
ance will be given to the patient. Third, the effects of a
combined treatment (i.e. both CCBT and treatment as
usual by a GP) still need to be evaluated. We think this
might have extra effects in terms of improvement in
depressive severity and quality of life. Although the GP is
not directly involved in the CCBT program, a combined
treatment might also increase adherence to the interven-
tion. Previous studies already showed that minimal thera-
pist contact could increase the adherence to Internet-
based interventions [85,86], a result which was recently
confirmed in a meta-analysis [87]. Next to that, the GP
can monitor the progress of the patient and can pay atten-
tion to non-verbal signals of the patient. Finally, only one
study so far has conducted an economic evaluation of
CCBT [27].
Methodological considerations
Our study has several strengths. First, we will recruit
patients from the general population. Unlike in samples
selected in general practices or clinics, no biases will occur
due to help seeking behaviour of patients and illness rec-
ognition by physicians, which is often a problem in
depression [10]. Another strength is that we will make full
use of the Internet infrastructure by administering allBMC Public Health 2008, 8:224 http://www.biomedcentral.com/1471-2458/8/224
Page 9 of 11
(page number not for citation purposes)
questionnaires online. This reduces the risk of making
mistakes while filling out or scoring the questionnaires.
Several limitations of the present study should also be
noted. All our outcomes will be measured online and one
may question the equality of computerised question-
naires and paper-and-pen versions. However, there are
sufficient indications that computerised and paper-and-
pen questionnaires show similar construct validity
[88,89]. Furthermore, all the outcomes at follow-up will
be measured by self-report and as a result information on
actual DSM-III diagnoses of depressive episodes at follow-
up will be lacking.
Conclusion
CCBT is a new treatment format with interesting possibil-
ities. It might offer a solution to the current undertreat-
ment of depression. It is a promising treatment for
depression in primary care, but more research needs to be
done before it can be disseminated and implemented in
the current health care system. The current study contrib-
utes to the growing literature on the clinical and cost-
effectiveness of online CCBT.
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